Les Tillack

Luina Bio Pty Ldt

Les Tillack is a Brisbane-based Biotech Expert and Entrepreneur whose perseverance, innovation, and ambition have all earned him the reputation as a seasoned industry leader. Les Tillack obtained a Bachelor of Science (B.Sc.) degree in Microbiology and a Bachelor of Engineering (B.E.) degree in Chemical Engineering from The University of Queensland. Les began working in the clinical pathology field in Brisbane. After 11 years, he was named Director of Operations at Progen Pharmaceuticals for another decade, where he spearheaded Progen’s anti-cancer drug PI-88’s progression from the preclinical stage to phase three manufacturing. Currently, Les Tillack serves as the CEO and Managing Director of Luina Bio (formerly known as PharmaSynth and previously affiliated with Progen), which is Australia’s frontrunner in the biopharmaceutical contract manufacturing space. At Luina Bio he has assembled a talented team that routinely delivers scientific excellence for their customers. In 2017, the company won the Queensland Export Award for Health & Biotechnology. Les strives to provide strategic advocacy to the biotechnology industry through new drug development for the greater good of humanity as a whole.